Literature DB >> 19040541

Possible mechanisms involved in the discrepancy of hepatic and aortic endothelial nitric oxide synthases during the development of cirrhosis in rats.

Morvarid Shir Mohammadi1, Dominique Thabut, Dominique Cazals-Hatem, Arnaud Galbois, Marika Rudler, Dominique Bonnefont-Rousselot, Richard Moreau, Didier Lebrec, Khalid A Tazi.   

Abstract

BACKGROUND/AIM: In cirrhosis, systemic nitric oxide (NO) overproduction and hepatic NO hypoproduction lead to arterial vasodilatation and portal hypertension. The mechanisms involved in these alterations in endothelial NO synthase (eNOS)-derived NO production in hepatic and systemic vasculature remain unknown. The aim of this study was to evaluate the regulation of eNOS and its major modulators in the liver and aorta during the development of cirrhosis in rats.
METHODS: Activated eNOS and Akt and expressions, and caveolin-1 (Cav-1) and scavenger receptor class B type I (SR-BI) expressions were measured before and 1, 2, 3 and 4 weeks after bile duct ligation. Plasma high-density lipoprotein (HDL) levels were measured.
RESULTS: Activated aortic eNOS increased at week 1, whereas it began to decrease at week 3 in the liver. Aortic expression of Cav-1 decreased at week 3 while hepatic expression increased by four-fold. Activated aortic Akt increased progressively while in the liver it gradually decreased during the development of cirrhosis. HDL levels decreased during the first week and decreased thereafter. The hepatic expression of SR-BI decreased.
CONCLUSION: This study shows that the modulation of Akt and Cav-1 is inverted in the liver and the aorta during the development of cirrhosis. In addition, decreased HDL levels may play a role in reduced hepatic eNOS activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19040541     DOI: 10.1111/j.1478-3231.2008.01909.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

Review 1.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

Review 2.  Splanchnic-aortic inflammatory axis in experimental portal hypertension.

Authors:  Maria-Angeles Aller; Natalia de las Heras; Maria-Paz Nava; Javier Regadera; Jaime Arias; Vicente Lahera
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

3.  AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.

Authors:  Liangshuo Hu; Lin Su; Zhixia Dong; Yunhua Wu; Yi Lv; Jacob George; Jianhua Wang
Journal:  J Mol Med (Berl)       Date:  2019-02-05       Impact factor: 4.599

4.  Exercise-Induced Changes in Caveolin-1, Depletion of Mitochondrial Cholesterol, and the Inhibition of Mitochondrial Swelling in Rat Skeletal Muscle but Not in the Liver.

Authors:  Damian Jozef Flis; Robert Antoni Olek; Jan Jacek Kaczor; Ewa Rodziewicz; Malgorzata Halon; Jedrzej Antosiewicz; Michal Wozniak; Rosita Gabbianelli; Wieslaw Ziolkowski
Journal:  Oxid Med Cell Longev       Date:  2015-12-29       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.